Necroptosis signaling adaptors in inflammatory diseases

炎症性疾病中的坏死性凋亡信号适配器

• 批准号: 9106004
• 负责人: FRANCIS Kaming CHAN
• 金额: $ 41.88万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9106004
• 关键词: Acute; Adjuvant; Agonist; Amyloid; Animals; Apoptosis; Area; Binding; Biochemical; Biological; Biology; Bone Marrow; CASP1 gene; CASP8 gene; Cell Death; Cell Nucleus; Cell membrane; Cells; Cessation of life; Chemicals; Chronic; Colitis; Colon Carcinoma; Colorectal Cancer; Complement; Complex; Cytokine Gene; Defect; Dendritic Cells; Disease; Epithelial Cell Proliferation; Epithelial Cells; Experimental Models; Gene Deletion; Gene Expression; Genetic Recombination; Genetic Transcription; Goals; Hematopoietic; ITGAX gene; Immune; Immunity; Immunobiology; Inflammation; Inflammatory; Inflammatory disease of the intestine; Injury; Interleukin-1; Interleukin-1 beta; Intestines; Knock-in Mouse; Lamina Propria; Lead; Light; Link; Lipopolysaccharides; Malignant Neoplasms; Mediating; Minor; Molecular; Molecular Chaperones; Mus; Mutagenesis; Nuclear; Nuclear Export; Nuclear Translocation; Pathway interactions; Pattern; Phosphotransferases; Physiological; Play; Population; Predisposition; Process; Protein Isoforms; Protein Kinase; RIPK1 gene; Reactive Oxygen Species; Recombinants; Reducing Agents; Reporter; Reporting; Role; Rupture; Sentinel; Signal Transduction; TLR3 gene; TLR4 gene; TNF gene; TNFRSF5 gene; Testing; Therapeutic; Tissues; Transcriptional Activation; base; cell type; chemokine receptor; cytokine; inhibitor-of-apoptosis protein; inhibitor/antagonist; interleukin-22; interleukin-23; macrophage; mutant; novel; prevent; programs; public health relevance; receptor; response; tissue repair

 DESCRIPTION (provided by applicant): Inflammation is a key biological response with essential roles in protective immunity and auto- inflammatory diseases. Necroptosis is a non-apoptotic form of cell death with pro-inflammatory effects due to the release of cellular danger signals from ruptured plasma membranes. Receptor interacting protein kinase 3 (RIPK3) is an essential adaptor for necroptosis downstream of TNF-like death receptors and toll-like receptor 3 (TLR3) and TLR4. Ripk3-deficient mice are protected from many inflammatory diseases driven by inhibition of caspase 8 or the cellular inhibitor of apoptosis (IAP) proteins. These results led to the widely accepted view that RIPK3 drives inflammation through necroptosis. In contrast to these results, we found that Ripk3-deficient mice developed more severe chemical-induced colitis. The increased intestinal inflammation in Ripk3-deficient mice was not due to changes in cell death. Rather, Ripk3-deficient mice were impaired for expression of IL-1β, IL-23 and IL-22. Consistent with the known function of these cytokines in intestinal tissue repair, we found that injury-induced intestinal epithelial cell (IEC) proliferation was defective in Ripk3-deficient mice. These results indicate that immune sentinels in the intestinal lamina propria require RIPK3 to initiate a cytokine-driven tissue repair program. We found that in bone marrow derived dendritic cells (BMDCs), RIPK3 is required for IL-1β and IL-23 expression in response to stimulation with lipopolysaccharide (LPS), a TLR4 agonist. Similar to Ripk3-deficient mice treated with colitis-causing agent, reduced cytokine expression in Ripk3-deficient BMDCs was not due to reduced cell death. Rather, it was caused by defective activation of NF-B activation and impaired processing of pro-IL-1β. Specifically, RIPK3 is required for optimal activation of RelB-p50 heterodimer to promote IL-23 expression. In contrast, RIPK3 is not required for activation of RelA, c-Rel or p52. In addition, RIPK3 also promotes caspase 1 and caspase 8-mediated processing of pro-IL-1. These results indicate that RIPK3 critically controls RelB/p50-dependent IL-23 expression and pro-IL-1β processing and that these necroptosis-independent signaling functions are crucial for reparative inflammation. Based on these results, we propose two aims to investigate the molecular mechanisms by which RIPK3 regulates inflammatory cytokine expression in tissue repair responses. In Aim 1, we will study the biochemical mechanisms that controls RIPK3-mediated RelB-p50 nuclear translocation in BMDCs and CX3CR1+ macrophages from intestinal lamina propria. We hypothesize that RIPK3 and TRIF binding via the "RIP homotypic interaction motif" (RHIM) is critical for RelB-p50 activation and cytokine gene transcription. Moreover, we hypothesize that unlike necroptosis, this RHIM-mediated interaction does not involve amyloid conversion, RIPK1 or RIPK3 kinase activities. However, it is controlled by reactive oxygen species (ROS). We further hypothesize that upon activation by TRIF, RIPK3 functions as a chaperon to facilitate RelB-p50 nuclear translocation through direct binding to RelB. In addition to RelB-p50, we hypothesize that RIPK3 also promotes pro-IL-1 processing through an atypical RIPK1-RIPK3-FADD-caspase 8 complex. Moreover, cFLIP-long form binding to this complex critically promotes IL-1 secretion by preventing caspase 8-mediated apoptosis. In Aim 2, we will test the hypothesis that CX3CR1+ inflammatory macrophages in the intestinal lamina propria are the key immune effectors that produce IL-1 and IL-23 in a RIPK3-dependent manner. To test our hypothesis, we will use Cre-mediated recombination to generate mice with specific inactivation of RIPK3 in CD11c+ or CX3CR1+ cells. In addition, we will use mice expressing kinase inactive versions of RIPK1 and RIPK3 to determine the role of kinase activity in RIPK3-dependent cytokine expression and colitis induction. We will further test the hypothesis that correcting the early defect in cytokine expression and tissue repair can minimize chronic inflammation and susceptibility to inflammation-induced colon cancer. Successful completion of these studies will greatly enhance our understanding of the immunobiology of and relationship between RIPK3, dendritic cells/macrophages, necroptosis, tissue repair, inflammatory diseases and cancers.